Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Stage of Development | 7 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Therapy Area | 8 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Indication | 9 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Products under Development by Companies | 12 | 2 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Assessment | 14 | 5 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 2 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Companies Involved in Therapeutics Development | 19 | 4 |
| Naia Limited | 19 | 1 |
| Shire Plc | 20 | 1 |
| Tasly Pharmaceutical Group Co., Ltd. | 21 | 1 |
| Zealand Pharma A/S | 22 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Drug Profiles | 23 | 12 |
| FE-203799 Drug Profile | 23 | 1 |
| glepaglutide Drug Profile | 24 | 2 |
| GXG-8 Drug Profile | 26 | 1 |
| NB-1002 Drug Profile | 27 | 1 |
| teduglutide Drug Profile | 28 | 5 |
| ZPGG-23 Drug Profile | 33 | 1 |
| ZPGG-72 Drug Profile | 34 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Dormant Projects | 35 | 1 |
| Glucagon Like Peptide 2 Receptor (GLP2R) Featured News &Press Releases | 36 | 13 |
| Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) | 36 | 1 |
| May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome | 37 | 1 |
| Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 | 38 | 1 |
| Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome | 38 | 1 |
| Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX | 39 | 1 |
| Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan | 39 | 1 |
| Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data | 40 | 1 |
| Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association s (ADA) 74th Scientific Sessions | 41 | 1 |
| Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome | 41 | 1 |
| Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection | 42 | 1 |
| Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome | 43 | 1 |
| Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting | 44 | 1 |
| Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome | 45 | 2 |
| Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults | 47 | 1 |
| Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome | 47 | 2 |
| Appendix | 49 | 2 |
| Methodology | 49 | 1 |
| Coverage | 49 | 1 |
| Secondary Research | 49 | 1 |
| Primary Research | 49 | 1 |
| Expert Panel Validation | 49 | 1 |
| Contact Us | 49 | 1 |
| Disclaimer | 50 | 1 |